Advances in the Standard of Care in TNBC: Addressing Health Disparities and Integrating ADCs Into Treatment - a podcast by ReachMD

CME credits: 1.00

Valid until: 18-01-2023

Claim your CME credit at https://reachmd.com/programs/cme/advances-standard-care-tnbc-addressing-health-disparities-and-integrating-adcs-treatment/13107/

For patients with recurrent unresectable or metastatic triple negative breast cancer (TNBC), standard systemic therapy has largely consisted of chemotherapy, though the outlook has improved recently following FDA approval of several targeted therapies and immunotherapeutic options. The management of TNBC remains quite challenging for clinicians, particularly in light of persistent disparities in TNBC care that disproportionately impact specific patient populations (eg, women of minoritized populations). Racial disparities specific to TNBC include a higher incidence, more advanced stage at diagnosis, and increased mortality among black women versus white women in the United States.

This web-based, on-demand, activity will review health disparities and inequities in TNBC and how they impact care, along with the latest evidence for current and emerging antibody-drug conjugates and immunotherapeutic agents, to assist oncology professionals in delivering impartial care to all patients.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD